Can Xtant Medical Holdings Inc (NYSEAMERICAN:XTNT)’s Tomorrow Be Different? The Stock Had Decline in Shorts

June 16, 2018 - By Winifred Garcia

The stock of Xtant Medical Holdings Inc (NYSEAMERICAN:XTNT) registered a decrease of 10.29% in short interest. XTNT’s total short interest was 146,500 shares in June as published by FINRA. Its down 10.29% from 163,300 shares, reported previously. With 19,500 shares average volume, it will take short sellers 8 days to cover their XTNT’s short positions. The short interest to Xtant Medical Holdings Inc’s float is 1.26%.

The stock increased 1.23% or $0.08 during the last trading session, reaching $6.58. About 59,318 shares traded or 29.95% up from the average. Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) has risen 19.38% since June 16, 2017 and is uptrending. It has outperformed by 6.81% the S&P500.

Xtant Medical Holdings, Inc. develops, makes, and markets regenerative medicine products and devices in the United States and internationally. The company has market cap of $86.05 million. The Company’s biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; and OsteoWrap that wraps around non-union fractures to assist with fusion, as well as could be used in conjunction with a hardware plate system. It currently has negative earnings. The firm also provides BacFast HD facet stabilization dowels; OsteoSTX for posterolateral spine surgery applications, including scoliosis procedures; hMatrix dermal scaffold, an acellular matrix made from donated human dermal tissue that is used to replace a patient??s damaged tissue; and 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: